CM
PBYI icon

Crestline Management’s Puma Biotechnology PBYI Stock Holding History

Crestline Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-35,832
Closed -$190K – 188
2024
Q1 		$190K Buy
35,832
+1,058
+3% +$5.7K 0.02% 157
2023
Q4 		$151K Buy
34,774
+2,135
+7% +$7.07K 0.01% 157
2023
Q3 		$85.8K Hold
32,639
– – 0.01% 142
2023
Q2 		$115K Buy
32,639
+755
+2% +$2.35K 0.01% 148
2023
Q1 		$98.5K Buy
31,884
+3,388
+12% +$12.8K 0.01% 157
2022
Q4 		$121K Buy
28,496
+291
+1% +$1K 0.02% 163
2022
Q3 		$67K Hold
28,205
– – 0.01% 199
2022
Q2 		$80K Sell
28,205
-366
-1% -$910 0.01% 212
2022
Q1 		$82K Buy
+28,571
New +$73.9K 0.01% 254
2019
Q3 		– Sell
-32,000
Closed -$407K – 100
2019
Q2 		$407K Buy
+32,000
New +$737K 0.05% 75
2018
Q3 		– Sell
-18,132
Closed -$1.07M – 211
2018
Q2 		$1.07M Buy
+18,132
New +$1.05M 0.11% 191
2017
Q3 		– Sell
-15,685
Closed -$1.37M – 165
2017
Q2 		$1.37M Buy
15,685
+2,785
+22% +$156K 0.18% 65
2017
Q1 		$480K Buy
+12,900
New +$471K 0.09% 87

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Crestline Management's PBYI Position: Q2 2024 in Review

Crestline Management sold out of Puma Biotechnology (PBYI) in Q2 2024, closing a stake of 35,832 shares — an estimated $190K sold.

Crestline Management first reported a position in PBYI in Q1 2017 and held it in 13 quarters. The position peaked at $1.37M in Q2 2017. 99 funds tracked by Wall St. Rank hold PBYI as of Q2 2024.

  • Crestline Management reported no remaining Puma Biotechnology position as of Q2 2024 after selling out during the quarter.
  • Crestline Management sold 35,832 Puma Biotechnology shares in Q2 2024, an estimated $190K.
  • Crestline Management first reported a position in Puma Biotechnology in Q1 2017 and held it in 13 quarters.
  • Crestline Management's Puma Biotechnology position peaked at $1.37M in Q2 2017.
  • 99 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2024.

Based on Crestline Management's 13F filing for Q2 2024, filed 14 Aug 2024.